Morgan Stanley lowered the firm’s price target on Amgen to $303 from $310 and keeps an Equal Weight rating on the shares. MariTide diabesity development “continues to dominate the conversation” and the next update from the Phase 2 trial is expected in Q4, the analyst tells investors in a Q2 earnings preview note for the Biopharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN: